Dirk Wildemeersch

ORCID: 0000-0001-9005-7665 · 7 papers in corpus
letter 2016
Response to “A new approach to the management of ovarian endometrioma to prevent tissue damage and recurrence”
Reproductive BioMedicine Online ·doi:10.1016/j.rbmo.2016.04.010
article 2007
Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up
·doi:10.1016/j.maturitas.2006.12.004

ObjectivesLevonorgestrel (LNG), delivered locally into the uterine cavity has a profound effect on the endometrium. The aim of the study was to use a LNG intrauterine system to treat non-atypical and atypical endometrial hyperplasia in wome…

article 2003
Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy
·doi:10.1016/j.maturitas.2003.07.002

ObjectiveTo evaluate the pharmacodynamic effects of a novel intrauterine drug delivery system, FibroPlant-levonorgestrel (LNG), on the endometrium in 24 postmenopausal women using estrogen substitution therapy (EST) to suppress climacteric …

review 2003
Miniature, Low‐Dose, Intrauterine Drug‐Delivery Systems
·doi:10.1196/annals.1290.020

The safety of systemically administered sex steroids continues to be a major focus of researchers. The negative results of the Women's Health Initiative study (WHI), and follow-up reports published in JAMA, evaluating the safety of estro-pr…

review 2002
Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience
Reproductive BioMedicine Online ·doi:10.1016/s1472-6483(10)61919-0

A low-dose levonorgestrel (LNG)-releasing intrauterine system (IUS) (FibroPlant) has been clinically developed since 1997 for endometrial suppression during hormone replacement therapy in peri- and postmenopausal women, for the treatment of…

article 2001
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study
·doi:10.1080/713604208

AbstractObjective To evaluate the effect on menstrual blood loss of a novel 'frameless' intrauterine drug delivery system, the FibroPlant™ levonorgestrel intrauterine system (IUS), releasing 14 μg of levonorgestrel/day. An ancillary objecti…

article 2001
Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception ·doi:10.1080/ejc.6.4.192.198

OBJECTIVES: To evaluate the effect on menstrual pain in women with primary and secondary dysmenorrhea of a novel 'frameless' intrauterine drug delivery system (IUS), FibroPlant-levonorgestrel (LNG) (Contrel Research, Belgium), releasing 14 …